Insight

ESHIMMUNE2024 starts in exactly one month

Photo taken from ESH/X

Aug 14, 2024, 14:12

ESHIMMUNE2024 starts in exactly one month

The ESH 3rd Translational Research Conference on Immune and Cellular Therapies: Focus on Advanced Gene-Engineered Immune Cells 2024 (ESHIMMUNE2024) will be held in Dublin from September 13-15th, 2024.

The ESH 3rd Translational Research Conference on Immune and Cellular Therapies: Focus on Advanced Gene-Engineered Immune Cells offers a program featuring basic and clinical science, alongside opportunities for informal scientific exchange with leading global experts in the field.

This conference welcomes an international audience of biologists and clinicians, including trainees, and aims to unite those interested in immune and cellular therapies with a focus on advanced gene-engineered immune cells.

Participants can expect presentations of new data and important discussions on how to apply these insights to the future of immune and cellular therapies.

This educational conference has been approved for 19,5 CME-CPD credit points by the European Board for Accreditation in Haematology (EBAH).

The scientific topics that will be included at the ESHIMMUNE2024 will be as follows:

–Clinical development of CAR-T cell therapy.
– Emerging targets for cell therapy.
– Receptor engineering for tumor therapy.
– Gene editing to enhance efficacy.
– Novel cell types and sources – beyond autologous.
– Engineering immune cells in vivo.
– Correlative analyses of response and resistance.
– Overcoming barriers to improve response.
– The future of engineered cell therapy.

The European School of Haematology shared on X:

“ESHIMMUNE2024 starts in exactly one month!

3rd Translational Research Conference, Immune and cellular therapies.

Date: Sept. 13-15, 2024

Location: Malahide (Dublin)

Chairs: Chiara Bonini, Michael Hudecek, Stanley Riddell.”

For more posts like these, visit oncodaily.com.

cancer CAR T-cell therapy Chiara Bonini EBAH ESH ESHIMMUNE2024 European Board for Accreditation in Haematology European School of Haematology Haematology immune cells Michael Hudecek OncoDaily Oncology Stanley Riddell

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage